Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NHLLSmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVvRXHBWOi53LUG1JI5O NG\QNHY4OiCq MVTpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mmn1NlU4QTB7MEe=
U2932  MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M13CfVIvPS1zNTDuUS=> M2T4ZVczKGh? MoD0bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXGyOVc6ODlyNx?=
OCI-LY7 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MViyMlUuOTVibl2= MnvFO|IhcA>? NGfEWWNqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NWmwXmVtOjV5OUC5NFc>
Farage NWDmbndsS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml\oNk42NTF3IH7N NETQZnE4OiCq MnXVbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NIHXWGEzPTd7MEmwOy=>
LY7/EBV MorsR4VtdCCYaXHibYxqfHliQYPzZZk> MWGyMlUuOTVibl2= NWjuWId6PzJiaB?= NV3ZelRHcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MXiyOVc6ODlyNx?=
U2932/EBV NIj4NVVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXSyMlUuOTVibl2= NITpfW04OiCq M4PHOYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MVKyOVc6ODlyNx?=
HCT116 NH;rbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHucHJUPS13MECwJI5O NVjW[IpjOjRiaB?= MoXaSG1UVw>? MWXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M4TBXFI2PDl{NUG1
ACH-2 MnPzSpVv[3Srb36gRZN{[Xl? M{n4VVEuQSCwTR?= M1nUdlI1KGh? M4H4[4lv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> MXuyOVE1QTR4Nx?=
MCF-10A NXXuT3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\z[VJKSzVyPUCuNVfDuTBwMEGgcm0> M1TCN|I1QTV2OEW2
MCF-7 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKwTWM2OD1zLkGwxtExNjJyIH7N M1vnWVI1QTV2OEW2
SK-BR-3 M2rUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\2VGlEPTB;MT6wNOKyOC5|NTDuUS=> NXHpXZhkOjR7NUS4OVY>
MDA-MB-231 NVHlR2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu0TWM2OD1yLk[4xtExNjF2IH7N NISybW8zPDl3NEi1Oi=>
PC3 M4myNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LWfWlEPTB;MT62OeKyOC5|NTDuUS=> NVm3d41TOjR7NUS4OVY>
HCT116 M2nKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HJdWlEPTB;MT6wNOKyOC5yMDDuUS=> MWOyOFk2PDh3Nh?=
HCT116-p21-/- NV35PWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\oXmlEPTB;MT6yOuKyOC5|NzDuUS=> MkTaNlQ6PTR6NU[=
S1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW5TWM2OD15Lk[3xtExNjJ7IH7N M335WFI1QTV2OEW2
SW620 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwOURCtVAvOjlibl2= MXqyOFk2PDh3Nh?=
LOX-IMVI MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;DUY1pUUN3ME2wMlg4yrFyLkCzJI5O MkfkNlQ6PTR6NU[=
UACC-62 M4rvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfxeVhLUUN3ME2wMlU3yrFyLkG2JI5O Mn\LNlQ6PTR6NU[=
MDA-MB-435 NFP5XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISzV4NKSzVyPUCuPVDDuTBwME[gcm0> MUCyOFk2PDh3Nh?=
SF-295 NWHsUGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;5TWM2OD1yLki4xtExNjF3IH7N NFjvOXQzPDl3NEi1Oi=>
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XUeGlEPTB;MT6yOuKyOC5{NDDuUS=> NXf1ZYRYOjR7NUS4OVY>
H460 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17S[WlEPTB;Mj61POKyOC56MDDuUS=> MYKyOFk2PDh3Nh?=
EKVX NE\nUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwM{RCtVAvOzRibl2= NGe5bnMzPDl3NEi1Oi=>
H146 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i1OmlEPTB;MD6yNuKyOC5yNzDuUS=> NHf5NFkzPDl3NEi1Oi=>
H526 NGTQdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfzboZKSzVyPUCuNVXDuTBwMEOgcm0> NVPlflFuOjR7NUS4OVY>
HuT-78 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwN{RCtVAvPDRibl2= MXuyOFk2PDh3Nh?=
HA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrlblkxNjZ{NT2xNI5O Mk\sOFghcA>? NWLncGpWcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MoHGNlQ4PzF3MUC=
MS-275 MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13WSlAvPjJ3LUGwcm0> NFOyd2Y1QCCq NH;5cJFqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? NVLoU|hQOjR5N{G1NVA>
CD4 T NY\ob453T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoOFghcA>? Mlj2SWM2OD12LkZCtVEvOCCwTR?= NFLRRWkzPDd{MkS1OC=>
CD4 T NFXwTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPS2E1QCCq NEHnPVZESzVyPUGwO:KyOTJ4IH7N M{fqelI1PzJ{NEW0
CD4+ T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrQOZNSTUN3ME2zJI5O NI\t[ogzPDR7NUGwOS=>
A549 NUDpd3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnjS5p4OTEkgKOxNFDDqG6P M2i5[FI1NzN4L{S4JIg> MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NIrndHAzPDR6NUe5PS=>
JJN3 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGyOE81QCCq MmHoSWM2ODxz4pEJcm08KDR64pEJbC=> MnzINlQxOzBzNUC=
OPM-2 NVHPTZAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\pXowzPC92ODDo MlroSWM2OHN;MfMAjY5OQyB2OPMAjYg> NGXmbVMzPDB|MEG1NC=>
RPMI-8226 NHW5cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LVVlI1NzR6IHi= NHv3XWRGSzVyc{2xMljjiImwTUugOFjjiImq MWeyOFA{ODF3MB?=
U266 NGLUNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrjXHlPOjRxNEigbC=> MkjJSWM2OHN;MUFihKlvVTtiNElihKlp NEm0d3EzPDB|MEG1NC=>
CA46 MlqxRZBweHSxc3nzJGF{e2G7 MYq2JIg> NXHvXZhMcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NVrCbXE4OjN7Nk[xOlQ>
DG75 M2HuWGFxd3C2b4Ppd{BCe3OjeR?= MnvtOkBp MYDpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> MYSyN|k3PjF4NB?=
Ramos NVnUXYY5SXCxcITvd4l{KEG|c3H5 NW\mTmxqPiCq M3m2cYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> MYeyN|k3PjF4NB?=
ST486 NHTNU3dCeG:ydH;zbZMhSXO|YYm= MlTwOkBp MYrpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MVKyN|k3PjF4NB?=
HuT78 MVzBdI9xfG:|aYOgRZN{[Xl? NEDNfJAyNzFyL{GwNEBvVQ>? MoTNOFghcA>? M{LHW4lv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= MkXCNlM2OzJ5M{K=
DpVp35 NIXQSlBCeG:ydH;zbZMhSXO|YYm= MoiyNU8yOC9zMECgcm0> NV25cnI4PDhiaB?= NYjaRW1ocW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NULtU5o4OjN3M{K3N|I>
DpVp50 NYD6Xms1SXCxcITvd4l{KEG|c3H5 M3zNXFEwOTBxMUCwJI5O NGLHTFA1QCCq MWfpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? Mo\iNlM2OzJ5M{K=
DpP75  M1rjV2Fxd3C2b4Ppd{BCe3OjeR?= Mn25NU8yOC9zMECgcm0> MWS0PEBp M4D0ZYlv\HWlZYOgZox2dnRiYYDvdJRwe2m| Mn3hNlM2OzJ5M{K=
SKOV-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG4NgKBmzJybl2= NWDvU5dUPzJiaB?= NGLtVZhFVVOR M2jz[ZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M2\Ie|I{ODFyM{S4
Brca1 WT NEP6bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCx5qCUOjCwTR?= NHXVc|A4OiCq NHHsZlZFVVOR MWDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M2PrTlI{ODFyM{S4
Brca1 Null NX\xOVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYZ|Yy6oDVMkDuUS=> MXW3NkBp NV7reXZxTE2VTx?= NWLYWYw5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NHP1RW4zOzBzMEO0PC=>
OVCAR-8  NH3RUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfrNnQ6OeLCk{Kwcm0> NXO0RoZDPzJiaB?= MUjEUXNQ MnrOdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NGrqS5UzOzBzMEO0PC=>
NCI/ADR-RES M3;XTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxNgKBmzJybl2= MWe3NkBp MnvlSG1UVw>? MonMdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NV7RW3VjOjNyMUCzOFg>
HCT116 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq1JI5ONTVyIN88US=> M1r2TFI1KGh? M{\DNWROW09? MoPsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MYiyNlkzPDl3OB?=
RKO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITJ[pY2KG6PLUWwJO69VQ>? MlzLNlQhcA>? MUHEUXNQ NGjFdJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NEjwOXYzOjl{NEm1PC=>
CO115 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK1JI5ONTVyIN88US=> MlflNlQhcA>? MWrEUXNQ M3fHc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NV;OSI5YOjJ7MkS5OVg>
HFS Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHFbpdqPSCwTR?= M4e2dVI1NzR6L{eyJIg> MlnUbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MV[yNlExPjJ6Mh?=
LNCaP MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGyNVVSPSCwTR?= M1zKNVI1NzR6L{eyJIg> NGr3OnJqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MWWyNlExPjJ6Mh?=
A549 NIr2OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTmT404PSCwTR?= NYPHe4t6OjRxNEivO|IhcA>? MknpbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> Ml\aNlIyODZ{OEK=
697  NWDIPJhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDEWmljUUN3MPMAjV3jiIl{LkZCpI5O MXqyNVU{QDJzNh?=
697-R NULzN4xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4bmJKSzVy4pEJQgKBkThwNtMgcm3DqA>? MWWyNVU{QDJzNh?=
HUT78 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXqN3dKSzVyPUGgcm0> Mlm5NlEyQTh3NEW=
THJ-16T M1fhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexJI5O MYCyOEBp M3rVSIlvcGmkaYTzJINmdGxiZ4Lve5Rp NWXweFFuOjB6MUC1Olg>
HCT116 NVy0RoxFTnWwY4Tpc44hSXO|YYm= M1\LdFIxKG6P MoOxPEBp NG\aUFlud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= NG\QXJgzODd|OUS1OC=>
B104  NUm2SWNLTnWwY4Tpc44hSXO|YYm= NVriPHp3OiCwTR?= MkTyNlQwPDhxN{KgbC=> M1LvS4lv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= M17qcFIxPjh4NUC1
HL-60  MYXDfZRwfG:6aXPpeJkhSXO|YYm= NFPTSVkyNTVyMDDuUS=> NYDPcm1UOjRiaB?= MnjibY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NH3YcXQzODZ{NEG2Ny=>
HP100 M1XwcGN6fG:2b4jpZ4l1gSCDc4PhfS=> M{XxU|EuPTByIH7N NIjKcXEzPCCq MYPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MoPJNlA3OjRzNkO=
HL-60  MVzGeY5kfGmxbjDBd5NigQ>? MV6xNEBvVQ>? NGjpcmo1NzZxMU[gbC=> M1\NUolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= Mof3NlA3OjRzNkO=
HP100 NIjZbVVHfW6ldHnvckBCe3OjeR?= NGPsVJYyOCCwTR?= M3L4VFQwPi9zNjDo NVHzNpdbcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NIjxW40zODZ{NEG2Ny=>
HL-60  M37nTmZ2dmO2aX;uJGF{e2G7 Mo\rNVAuPTByIH7N M4DoTlQhcA>? NXTvNWhi\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MoryNlA3OjRzNkO=
HP100 NVjxSplWTnWwY4Tpc44hSXO|YYm= MUWxNE02ODBibl2= M{TtO|QhcA>? MWrk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MYmyNFYzPDF4Mx?=
11z MWrLbY5ie2ViQYPzZZk> MVGzMVExOCCwTR?= NUjmeWpHemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= MUmyNFYxPTF2NB?=
SKOV-3 M4\rT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC5OE85NzF4IH7N MX[0PEBp Mk\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> Ml3lNlA1ODR3NkS=
OVCAR-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7LUpI2PC96L{G2JI5O M{D6fVQ5KGh? MnvjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NFu1So8zODRyNEW2OC=>
HBL-2 NFHqSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnhTpEzNTFyIH7N MXSyOEBp NES2XFNKSzVyPUSuN{BvVQ>? MoW1NlAxPjhyOEC=
Jeko-1 NWS1U5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\lWmQzNTVyIH7N NHzCPVQzPCCq NFqzOo5KSzVyPUGxJI5O NHHEeYszODB4OEC4NC=>
Granta-519 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW1MVQxKG6P MonYNlQhcA>? MmC5TWM2OD13OD61JI5O NWHTTXp3OjByNkiwPFA>
L1236 M4LzS2N6fG:2b4jpZ4l1gSCDc4PhfS=> MkXKNUBvVS1zMECg{txO MoPOOFghcA>? MmTXSWM2OD1yLkC3JO69VQ>? MkTDNVkzOzN2N{C=
L428 NHP0b3JEgXSxdH;4bYNqfHliQYPzZZk> MUixJI5ONTFyMDFOwG0> M1LkZVQ5KGh? M16yOWVEPTB;MD60N{DPxE1? Mn2xNVkzOzN2N{C=
KM-H2 M2PwUmN6fG:2b4jpZ4l1gSCDc4PhfS=> NEXNWZYyKG6PLUGwNEDPxE1? Ml;qOFghcA>? NVHVNXU3TUN3ME2wMlU5KM7:TR?= NE\0fXgyQTJ|M{S3NC=>
L540Cy MVXDfZRwfG:6aXPpeJkhSXO|YYm= MkHuNUBvVS1zMECg{txO NUjGXHF6PDhiaB?= M1:3cGVEPTB;MD6xOkDPxE1? MlHFNVkzOzN2N{C=
G401 MXrGeY5kfGmxbjDBd5NigQ>? MVWxNEBvVQ>? NIPQW2IzPC92OD:3NkBp MXrEUXNQ NETzcIlqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MVOxPVIzOTV6Nh?=
STM91-01 MV;GeY5kfGmxbjDBd5NigQ>? MWKxNEBvVQ>? M175VFI1NzR6L{eyJIg> NXPacZN7TE2VTx?= M2\vTYlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NWXaVlFqOTl{MkG1PFY>
SJSC  NEfqdoNHfW6ldHnvckBCe3OjeR?= NWjmbo1wOTBibl2= NUj0W5lDOjRxNEivO|IhcA>? MYDEUXNQ MXLpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NUPTO|g1OTl{MkG1PFY>
BT16  MXjGeY5kfGmxbjDBd5NigQ>? M4j2eVExKG6P NYXtbmQxOjRxNEivO|IhcA>? NETk[|NFVVOR NVfzU25[cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MXSxPVIzOTV6Nh?=
NCI-H1299 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTtR2RKUUN3ME20MlbDuTBwMjDu[{9udA>? NFLFW5cyQTF5OUi5NC=>
NCI-2882 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLl[4RKSzVyPUGuOuKyOC5yNDDu[{9udA>? NXO2THRTOTlzN{m4PVA>
HCC95 M4Tq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwNdMxNE4xPSCwZz;tcC=> NGTMPYkyQTF5OUi5NC=>
NCI-H23 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTBTWM2OD1{LkpCtVAvOiCwZz;tcC=> NVXvTGRqOTlzN{m4PVA>
NCI-H157 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13VZWlEPTB;MT62xtExNjB{IH7nM41t MnOzNVkyPzl6OUC=
NCI-H460 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jpPWlEPTB;Mj6xxtExNjB5IH7nM41t NXH5[oVnOTlzN{m4PVA>
NCI-H1975 NVHE[m5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5R2lEPTB;MT6zxtExNjB2IH7nM41t NITvNnAyQTF5OUi5NC=>
NCI-H820 M{LqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWyTWM2OD1{LkVCtVAvOSCwZz;tcC=> NFK0XJIyQTF5OUi5NC=>
NCI-H1650 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjDTWM2OD12LkpCtVAvOyCwZz;tcC=> NFjTOVUyQTF5OUi5NC=>
DTC1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX25ZnRzUUN3ME2wMlUyKG6P MXWxPFU3PjJ2Nh?=
KAO NHXVfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHyTWM2OD1yLkmxJI5O M4n6dlE5PTZ4MkS2
SU-CCS-1 NV25NmxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1R5dKSzVyPUCuPFkhdk1? NFrNNngyQDV4NkK0Oi=>
SYO-1 M3n3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWblFNUUN3ME2wMlY4KG6P MkDqNVg2PjZ{NE[=
FUJI NG[2NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\rXYFKSzVyPUGuN|Ehdk1? NELWXlYyQDV4NkK0Oi=>
SKNMC Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvxTWM2OD1zLkG3JI5O NEnmSmQyQDV4NkK0Oi=>
402-91 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjxTWM2OD1zLkK2JI5O NIDJWJIyQDV4NkK0Oi=>
1765-92 M3H5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\hTWM2OD1zLke3JI5O MWixPFU3PjJ2Nh?=
JN-DSRCT-1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzNW2xKSzVyPUGuNlUhdk1? M2fuVVE5PTZ4MkS2
NMS-2PC M3v1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGftNnVKSzVyPUCuPFEhdk1? M1zVSVE5PTZ4MkS2
HL60 M13TNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOE[gcm0> NUW3VnlGOTh3Nk[yOFY>
A549 M3PXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNwMkSgcm0> M4\v[VE5PTZ4MkS2
SW480 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;POWlEPTB;Mj62PUBvVQ>? MYWxPFU3PjJ2Nh?=
MCF7 NEPn[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLSTWM2OD1|LkW1JI5O NX\6OFU1OTh3Nk[yOFY>
PC-3 NFewWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm5PVRmUUN3ME2yMlUyKG6P NFXUTowyQDV4NkK0Oi=>
MMRU MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPlTWM2OD1{LkW3JI5O NFnVRoMyQDV4NkK0Oi=>
Hs68 NEm5RZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD5TWM2OD1-MUCgcm0> NHPLT|kyQDV4NkK0Oi=>
hMSC-001F MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRT5zMDDuUS=> MoDSNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID